Pfizer Scores Major Win in Prostate Cancer Trial with Talzenna Combo

PFE announced positive topline results from the Phase 3 TALAPRO-3 study, demonstrating that TALZENNA (talazoparib) combined with XTANDI (enzalutamide) significantly improved radiographic progression-free survival in patients with HRR gene-mutated metastatic castration-sensitive prostate cancer . The results markedly exceeded the pre-specified target hazard ratio of 0.63, with the majority of patients remaining progression-free at the time of analysis.

The trial enrolled 599 patients across the U.S., Canada, Europe, South America, and the Asia-Pacific region, and showed a strong trend toward improvement in overall survival, though the data were not yet mature. Secondary endpoints including overall response rate, duration of response, and time to PSA progression all showed improvements. No new safety signals were observed beyond the known profiles of the individual agents.

For PFE investors, the TALAPRO-3 win expands the potential market for the Talzenna-Xtandi combination into earlier-stage prostate cancer, a significantly larger patient population than the currently approved metastatic castration-resistant indication. Pfizer is expected to seek regulatory approval for this broader use, which could add meaningful revenue to the oncology franchise and help offset the company's ongoing post-COVID revenue normalization.